BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 18830928)

  • 1. BiovaxID, a personalized therapeutic vaccine against B-cell lymphomas.
    Reinis M
    Curr Opin Mol Ther; 2008 Oct; 10(5):526-34. PubMed ID: 18830928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity of a plasmid DNA vaccine encoding chimeric idiotype in patients with B-cell lymphoma.
    Timmerman JM; Singh G; Hermanson G; Hobart P; Czerwinski DK; Taidi B; Rajapaksa R; Caspar CB; Van Beckhoven A; Levy R
    Cancer Res; 2002 Oct; 62(20):5845-52. PubMed ID: 12384547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic lymphoma vaccines: importance of T-cell immunity.
    Neelapu SS; Lee ST; Qin H; Cha SC; Woo AF; Kwak LW
    Expert Rev Vaccines; 2006 Jun; 5(3):381-94. PubMed ID: 16827622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.
    Bertinetti C; Zirlik K; Heining-Mikesch K; Ihorst G; Dierbach H; Waller CF; Veelken H
    Cancer Res; 2006 Apr; 66(8):4496-502. PubMed ID: 16618777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BiovaxID idiotype vaccination: active immunotherapy for follicular lymphoma.
    Flowers CR
    Expert Rev Vaccines; 2007 Jun; 6(3):307-17. PubMed ID: 17542746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational development of vaccination strategies in follicular NHL.
    Sakamaki I; Qin H; Kwak LW
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):295-304. PubMed ID: 21658625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
    Hurvitz SA; Timmerman JM
    Expert Opin Biol Ther; 2005 Jun; 5(6):841-52. PubMed ID: 15952914
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a phase I clinical study.
    McCormick AA; Reddy S; Reinl SJ; Cameron TI; Czerwinkski DK; Vojdani F; Hanley KM; Garger SJ; White EL; Novak J; Barrett J; Holtz RB; Tusé D; Levy R
    Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10131-6. PubMed ID: 18645180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BiovaxID®: a customized idiotype vaccine for the treatment of B-cell lymphoma.
    Villanueva H; de Cerio AL; Inoges S; Pastor F; Soldevilla MM; Bendandi M
    Expert Rev Vaccines; 2011 Dec; 10(12):1661-9. PubMed ID: 22085168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Personalized immunotherapy for the treatment of non-Hodgkin's lymphoma: a promising approach.
    Vose JM
    Hematol Oncol; 2006 Jun; 24(2):47-55. PubMed ID: 16447298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphoma vaccine trial: one step forward in long trek.
    Schmidt C
    J Natl Cancer Inst; 2009 Sep; 101(18):1228-9, 1232. PubMed ID: 19738162
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase III randomized study of autologous lymphoma-derived idiotype specific vaccination plus GM-CSF in patients with follicular lymphoma in first complete remission.
    Clin Adv Hematol Oncol; 2003 Jan; 1(1):67. PubMed ID: 16227966
    [No Abstract]   [Full Text] [Related]  

  • 13. The role of idiotype vaccines in the treatment of human B-cell malignancies.
    Bendandi M
    Expert Rev Vaccines; 2004 Apr; 3(2):163-70. PubMed ID: 15056042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized immunotherapy for the treatment of non-Hodgkin lymphoma: a promising approach.
    Vose J
    Clin Adv Hematol Oncol; 2005 Dec; 3(12):923-32. PubMed ID: 16555434
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cloning of idiotype immunoglobulin genes in B cell lymphomas by anchored PCR and production of individual recombinant idiotype vaccines in Escherichia coli.
    Bertinetti C; Simon F; Zirlik K; Heining-Mikesch K; Pfeifer D; Osterroth F; Rosenthal FM; Veelken H
    Eur J Haematol; 2006 Nov; 77(5):395-402. PubMed ID: 16879605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines for lymphomas: idiotype vaccines and beyond.
    Houot R; Levy R
    Blood Rev; 2009 May; 23(3):137-42. PubMed ID: 18951668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer vaccine strategies get bigger and better.
    de Gruijl TD; Curiel DT
    Nat Med; 1999 Oct; 5(10):1124-5. PubMed ID: 10502808
    [No Abstract]   [Full Text] [Related]  

  • 18. BiovaxID: a personalized therapeutic cancer vaccine for non-Hodgkin's lymphoma.
    Lee ST; Jiang YF; Park KU; Woo AF; Neelapu SS
    Expert Opin Biol Ther; 2007 Jan; 7(1):113-22. PubMed ID: 17150023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment strategy for indolent B-cell lymphoma].
    Tobinai K
    Rinsho Ketsueki; 2001 Apr; 42(4):288-92. PubMed ID: 11400299
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of anti-idiotype vaccines in the modern treatment of human follicular lymphoma.
    Bendandi M
    Expert Rev Anticancer Ther; 2001 Jun; 1(1):65-72. PubMed ID: 12113135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.